Holmes Biopharma, Inc. (NASDAQ: LMB) reported Q4 EPS of ($0.45), $0.38 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $133.7 million versus the consensus estimate of $97 million.

GUIDANCE:

Holmes Biopharma, Inc. sees FY2017 revenue of $460-480 million.

For earnings history and earnings-related data on Holmes Biopharma, Inc. (LMB) click here.